Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Schizophrenia Clear all
Completed Phase 2 Interventional

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

NCT02624167
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
NW-3509A, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Garden Grove, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 17, 2026, 10:45 AM EDT
Terminated Phase 4 Interventional

Efficacy of Galantamine to Treat Schizophrenia

NCT00232349
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorder
Interventions
galantamine
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2008 · Synced Oct 17, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia

NCT00216281
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine augmented with atomoxetine up to 40 mg or placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

NCT00161044
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study

NCT02421146
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
Transcranial direct current stimulation, Transcranial direct current stimulation - Sham
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 17, 2026, 10:45 AM EDT
Not listed Not applicable Interventional

Evaluation of Programs of Coordinated Care and Disease Management

NCT00627029
View directory record Official record
Conditions
Congestive Heart Failure, Diabetes, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Cancer, Cerebrovascular Disease, Alzheimer's Disease, Psychotic Disorder, Major Depression
Interventions
Care Coordination
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
Not listed
Enrollment
18,277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Sunrise, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional

eMove - Dance/Movement Therapy Study

NCT05712928
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Dance/movement therapy (eMove)
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 17, 2026, 10:45 AM EDT
Terminated Not applicable Interventional

Aripiprazole Treatment of the Prodrome

NCT00169949
View directory record Official record
Conditions
Prodromal Schizophrenia, Prodromal Psychosis
Interventions
aripiprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
13 Years to 22 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

NCT00789698
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
Lurasidone HC1, Quetiapine XR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
27
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

NCT02411526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 17, 2026, 10:45 AM EDT
Terminated Not applicable Interventional Results available

tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia

NCT03588728
View directory record Official record
Conditions
Transcranial Direct Current Stimulation, Smoking, Cigarette, Schizophrenia
Interventions
Transcranial Direct Current Stimulation, Cognitive Remediation (CR)
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Integrated Care (IC) Models for Patient-Centered Outcomes

NCT03451630
View directory record Official record
Conditions
Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension, Anxiety, Atrial Fibrillation, Congestive Heart Failure, Depression, Bipolar Disorder, Schizophrenia
Interventions
High-Touch, High-Tech, Optimal Discharge Planning
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Understanding How Cognitive Remediation Works

NCT01683539
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression, Bipolar Disorder
Interventions
The Thinking Skills for Work Program, The Cognitive Skills for Work Program
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders

NCT01487668
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 4 Interventional

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

NCT00287820
View directory record Official record
Conditions
Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

NCT00825539
View directory record Official record
Conditions
Schizophrenia
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)

NCT00137280
View directory record Official record
Conditions
Schizophrenia, Chronic Illness, Weight Gain, Psychotic Disorder
Interventions
Collaborative Chronic Illness Care Model
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Long Beach, California • West Los Angeles, California • Shreveport, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714713
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
69
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714661
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
38
States / cities
Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

NCT01730768
View directory record Official record
Conditions
Schizophrenia
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Garden Grove, California • Glendale, California • National City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness

NCT01244854
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Chronic Affective Disorders, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)

NCT00119574
View directory record Official record
Conditions
Schizophrenia Disorders, Chronic Illness, Schizoaffective Disorder, Weight Gain
Interventions
Collaborative Chronic Illness Model
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Thinking Skills for Work in Severe Mental Illness

NCT01926613
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Anxiety Disorder
Interventions
Thinking Skills for Work Program, Supported Employment
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 17, 2026, 10:45 AM EDT